Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Eli Lilly’s weight loss drug Zepbound outperformed competitor Novo ... a 25% or more body weight reduction due to tirzepatide. By comparison, those who received semaglutide experienced a 16% ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

Participants achieved an average weight loss of 20.2% with Zepbound ... However, the study was not powered to compare the safety and tolerability of Zepbound and the safety and tolerability ...

Zepbound’s performance in this direct comparison strengthens Lilly’s position in the rapidly growing weight loss medication market. The drug operates as a dual GIP and GLP-1 receptor agonist ...

Injectable GLP-1 receptor agonist drugs Wegovy (semaglutide) and Zepbound (tirzepatide ... first to undertake a head-to-head comparison of the weight loss effectiveness of semaglutide and ...

Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing cancer ...

However, the study was not powered to compare the safety and ... one weight-related medical problem, to lose weight and keep it off. Additionally, Zepbound is FDA-approved to treat adults with ...